Green Cross Medical Science Corporation Cash Flow Conversion Efficiency

Latest as of June 2026: -0.013x

Green Cross Medical Science Corporation cash flow conversion efficiency. Based on the latest financial reports, Green Cross Medical Science Corporation (142280) has a cash flow conversion efficiency ratio of -0.013x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-714.99 Million ≈ $-484.54K USD) by net assets (₩56.08 Billion ≈ $38.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Green Cross Medical Science Corporation (2014–2025)

Cash flow conversion efficiency of Green Cross Medical Science Corporation from 2014 to 2025. This chart illustrates how Green Cross Medical Science Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Green Cross Medical Science Corporation (142280) stock price for real-time trading data and today's change.

Green Cross Medical Science Corporation Cash Flow Conversion Ratio Explained

Green Cross Medical Science Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Green Cross Medical Science Corporation Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Green Cross Medical Science Corporation ranked by their cash flow conversion efficiency. Also see Green Cross Medical Science Corporation stock valuation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Mondi PLC LSE:MNDI	0.049x
OS Therapies Incorporated NYSE MKT:OSTX	-1.000x
Aureus Greenway Holdings Inc. NASDAQ:PUSA	0.009x
Brand Group (M.G) Ltd TA:BRND	0.030x
Mobileleader Co.Ltd KQ:100030	0.014x
Oceanpal Inc NASDAQ:OP	-0.007x
Australian Vanadium Ltd AU:AVL	-0.040x
Adaptimmune Therapeutics plc F:473A	0.490x

Annual Cash Flow Conversion Efficiency for Green Cross Medical Science Corporation (2014–2025)

The table below shows the annual cash flow conversion efficiency of Green Cross Medical Science Corporation from 2014 to 2025. Review free cash flow generation of Green Cross Medical Science Corporation to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩46.37 Billion ≈ $31.42 Million	₩7.20 Billion ≈ $4.88 Million	0.155x	+74.72%
2024-12-31	₩41.21 Billion ≈ $27.93 Million	₩3.66 Billion ≈ $2.48 Million	0.089x	-22.67%
2023-12-31	₩36.92 Billion ≈ $25.02 Million	₩4.24 Billion ≈ $2.87 Million	0.115x	-64.89%
2022-12-31	₩33.25 Billion ≈ $22.54 Million	₩10.88 Billion ≈ $7.37 Million	0.327x	+164.94%
2021-12-31	₩36.11 Billion ≈ $24.47 Million	₩-18.20 Billion ≈ $-12.33 Million	-0.504x	-224.76%
2020-12-31	₩56.47 Billion ≈ $38.27 Million	₩-8.76 Billion ≈ $-5.94 Million	-0.155x	-87.24%
2019-12-31	₩49.58 Billion ≈ $33.60 Million	₩-4.11 Billion ≈ $-2.78 Million	-0.083x	-146.02%
2018-12-31	₩15.34 Billion ≈ $10.40 Million	₩-516.61 Million ≈ $-350.10K	-0.034x	-125.18%
2017-12-31	₩23.23 Billion ≈ $15.75 Million	₩3.11 Billion ≈ $2.11 Million	0.134x	-64.95%
2016-12-31	₩26.85 Billion ≈ $18.20 Million	₩10.25 Billion ≈ $6.94 Million	0.382x	+302.32%
2015-12-31	₩28.87 Billion ≈ $19.56 Million	₩-5.45 Billion ≈ $-3.69 Million	-0.189x	-167.97%
2014-12-31	₩31.50 Billion ≈ $21.35 Million	₩-2.22 Billion ≈ $-1.50 Million	-0.070x	--

About Green Cross Medical Science Corporation

KQ:142280 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$42.95 Million

₩63.38 Billion KRW

Market Cap Rank

#22274 Global

#1414 in Korea

Share Price

₩2915.00

Change (1 day)

-0.51%

52-Week Range

₩2395.00 - ₩6230.00

All Time High

₩19450.00